Astellas Pharma's Chief Financial Officer (CFO) Naoki Okamura speaks during a news conference at its headquarters in Tokyo, Japan, December 3, 2019. REUTERS/Kim Kyung-Hoon
TOKYO: Astellas Pharma Inc. agreed to buy Audentes Therapeutics Inc. for about $3 billion, the latest deal by a pharmaceutical company eager to push into promising gene-therapy technologies.
The Japanese drugmaker will pay $60 a share for San Francisco-based Audentes, according to a statement from the companies Tuesday, a 110% premium to Audentes’s closing price on Monday. The deal is expected to close in the first quarter of 2020.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
